Capital keeps flowing into ASX Biotech shares in 2021

What is driving capital inflow into ASX biotech shares?

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date.

Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain, one observes that this total increases to over $1 billion, according to today's Australian Financial Review.

Here, we examine just what is driving this recent trend in capital inflows towards ASX Biotech shares.

What is behind the surge in inflows to ASX Biotech shares this year?

There has been a spate of capital raised for ASX Biotech shares this year, such as Imugene Limited (ASX: IMU), Immutep Ltd (ASX: IMM) and Aroa Biosurgery Ltd (ASX: ARX).

For instance, Imugene recently "completed an upsized $95 million offer", issuing ~300 million additional shares at a price of 30 cents apiece.

Aroa also "banked $53 million in a placement and share purchase plan [SPP]" earlier this week to eligible investors at $1.165 per share. $5 million of this total is sought from the SPP.

There appears to be "four big reasons behind the recent flurry of [capital] raising" trends that have occurred this year.

These include the establishment of new equity-focused healthcare investment funds, outsized returns in the broad sector, and a cluster of collaborations with big pharmaceutical companies.

Moreover, it also appears the biotech sector "has the flavour of the month for investors", as per the Financial Review.

Bell Potter Securities analyst Darren Craike was quoted saying:

A lot of generalist funds are looking for alpha [above market return] in their portfolios…so many have started to gravitate to healthcare where there have been some exceptional returns in the last two to three years.

Moreover, the trends look set to continue for the time being, with a number of pre-IPO's on the cards.

To illustrate, Tissue Repair which is a regenerative medicine and aesthetic dermatology company, plans on "targeting a $25 million raise" via listing this year.

Additionally, upcoming biotech names Triad Lifesciences and Vitfrafy Lifesciences "are also confirmed to be pursuing listings" this year.

ASX Biotech shares snapshot

The basket of ASX Biotech shares contained within the S&P / ASX 200 Index (ASX: XJO) has provided a return of 116% since March of this year.

This select group has outpaced the overall broad index, which has posted a return of ~12.5% this year to date.

Such returns help to explain the attractiveness of ASX Biotech shares for Australian investors at the current standing.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »